The Role of lncRNAs in the Pathobiology and Clinical Behavior of Multiple Myeloma.
Arantxa Carrasco-LeonAne AmundarainNahia Gomez-EcharteFelipe ProsperXabier AgirrePublished in: Cancers (2021)
MM is a hematological neoplasm that is still considered an incurable disease. Besides established genetic alterations, recent studies have shown that MM pathogenesis is also characterized by epigenetic aberrations, such as the gain of de novo active chromatin marks in promoter and enhancer regions and extensive DNA hypomethylation of intergenic regions, highlighting the relevance of these non-coding genomic regions. A recent study described how long non-coding RNAs (lncRNAs) correspond to 82% of the MM transcriptome and an increasing number of studies have demonstrated the importance of deregulation of lncRNAs in MM. In this review we focus on the deregulated lncRNAs in MM, including their biological or functional mechanisms, their role as biomarkers to improve the prognosis and monitoring of MM patients, and their participation in drug resistance. Furthermore, we also discuss the evidence supporting the role of lncRNAs as therapeutic targets through different novel RNA-based strategies.
Keyphrases
- long non coding rna
- gene expression
- network analysis
- genome wide
- transcription factor
- dna methylation
- genome wide identification
- genome wide analysis
- copy number
- end stage renal disease
- multiple myeloma
- physical activity
- ejection fraction
- newly diagnosed
- dna damage
- prognostic factors
- single cell
- poor prognosis
- chronic kidney disease
- peritoneal dialysis
- case control
- single molecule
- cell free